For many individuals living with Treatment-Resistant Depression (TRD), the journey toward wellness has often been marked by a cycle of hope followed by the frustration of treatments that either didn’t work or stopped working too soon. When Spravato® (esketamine nasal spray) was first introduced, it offered a new mechanism of action—targeting the glutamate system rather than the traditional serotonin or norepinephrine pathways.
As we move through 2026, the conversation around Spravato has matured. It’s no longer just about the “rapid” relief it provides in the first 24 hours; it’s about the durability and sustainability of that relief over years of care.
1. Establishing Real-World Superiority
While early Phase 3 clinical trials demonstrated efficacy, the real-world evidence gathered through 2026 has confirmed even more robust outcomes in diverse clinical settings. A definitive January 2026 systematic review and meta-analysis published in the Journal of Affective Disorders synthesized data from over a dozen naturalistic cohorts, identifying a massive effect size (Hedges’ g = -1.98) for symptom reduction.
This translates to more than just clinical statistical significance; it represents a fundamental shift in how we manage treatment-resistant depression (TRD). Unlike traditional antidepressants, which often yield diminishing returns in real-world “naturalistic” settings compared to controlled trials, Spravato® has shown a “treatment-increasing” effect over time, where remission rates in clinical practice often exceed those reported in the original registration trials.
2. Safety and Maintenance: The 6.5-Year Perspective
Safety remains the cornerstone of any psychiatric intervention. The SUSTAIN-3 Study (Zaki et al., 2023), which provided up to 6.5 years of continuous maintenance data, reinforced the robust long-term safety profile of esketamine. This longitudinal evidence confirms that the anticipated transient side effects—such as temporary dissociation or blood pressure changes—remain predictable and manageable within the mandatory REMS (Risk Evaluation and Mitigation Strategy) environment.
Crucially, after more than half a decade of continuous observation, no new safety signals have emerged, providing both clinicians and patients with the confidence that esketamine is a viable option for extended maintenance when necessary.
3. Rapid Response in Acute Crisis
One of the most critical clinical applications of Spravato® is its use in patients with Major Depressive Disorder (MDD) who have active suicidal ideation with intent. The ASPIRE-I study (Journal of Clinical Psychiatry, 2020) demonstrated that esketamine nasal spray, when combined with standard therapeutic care, provides a rapid reduction in depressive symptoms within 24 hours.
While Spravato® is not a replacement for hospitalization or comprehensive crisis intervention, its ability to provide an immediate “physiological bridge” during the most dangerous windows of an acute depressive episode has established it as a foundational tool in emergency psychiatry.
The Oasis Perspective: Personalized Pathways
At Oasis Health Services, we don’t view Spravato as a standalone solution, but as a powerful catalyst within a broader, integrated care plan. We’ve seen firsthand how the rapid relief provided by Spravato can “open a window” for patients, making them more receptive to therapy and lifestyle changes that were previously impossible due to the weight of their depression.
In 2026, our approach is more data-driven than ever. We use clinical observation and cognitive tracking to personalize the frequency of treatment sessions, ensuring that we are providing the “minimum effective dose” to maintain long-term stability.
Recovery from TRD is rarely a straight line, but with the durability confirmed by the most authoritative clinical research, Spravato remains one of the most effective tools we have to help patients find their way back to a life they love.
References
- Reif A, et al. (2023). “Esketamine Nasal Spray vs. Quetiapine for Treatment-Resistant Depression.” New England Journal of Medicine. DOI: 10.1056/NEJMoa2304145
- Zaki N, et al. (2023). “Long-term safety and maintenance of response with esketamine nasal spray in treatment-resistant depression – final results of the SUSTAIN-3 study.” Neuroscience Applied. DOI: 10.1016/j.nsa.2023.102450
- Fu DJ, et al. (2020). “Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).” Journal of Clinical Psychiatry. DOI: 10.4088/JCP.19m13191
- Lapa de Oliveira C, et al. (2026). “Systematic review and meta-analysis of intranasal esketamine for treatment-resistant depression: Evidence from real-world studies.” Journal of Affective Disorders. DOI: 10.1016/j.jad.2026.121257